Cantor Fitzgerald Cuts Janux Therapeutics (NASDAQ:JANX) Price Target to $150.00

Janux Therapeutics (NASDAQ:JANX) had its price target lowered by Cantor Fitzgerald from $200.00 to $150.00 in a report released on Tuesday morning, MarketBeat reports. The firm currently has an overweight rating on the stock.

Other analysts have also recently issued reports about the company. Wedbush reaffirmed an “outperform” rating and issued a $76.00 price objective on shares of Janux Therapeutics in a research report on Friday, November 7th. Wall Street Zen raised Janux Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. HC Wainwright decreased their price objective on shares of Janux Therapeutics from $70.00 to $45.00 and set a “buy” rating on the stock in a report on Tuesday. Barclays raised their target price on shares of Janux Therapeutics from $47.00 to $48.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $45.00 price target on shares of Janux Therapeutics in a research note on Wednesday, September 10th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $62.67.

Janux Therapeutics Stock Performance

Shares of NASDAQ JANX opened at $16.40 on Tuesday. The stock has a market capitalization of $986.46 million, a PE ratio of -9.76 and a beta of 2.82. Janux Therapeutics has a 52 week low of $15.51 and a 52 week high of $71.71. The stock has a 50 day moving average price of $26.93 and a 200 day moving average price of $25.25.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $0.21. The firm had revenue of $10.00 million for the quarter, compared to the consensus estimate of $3.07 million. As a group, research analysts forecast that Janux Therapeutics will post -1.38 EPS for the current year.

Insider Buying and Selling

In related news, insider Andrew Hollman Meyer sold 16,665 shares of the company’s stock in a transaction dated Tuesday, October 28th. The shares were sold at an average price of $30.06, for a total transaction of $500,949.90. Following the completion of the sale, the insider owned 82,139 shares of the company’s stock, valued at $2,469,098.34. This represents a 16.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders sold a total of 23,331 shares of company stock valued at $710,862 over the last three months. 8.10% of the stock is owned by insiders.

Institutional Investors Weigh In On Janux Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Quinn Opportunity Partners LLC grew its holdings in Janux Therapeutics by 15.4% during the 2nd quarter. Quinn Opportunity Partners LLC now owns 59,893 shares of the company’s stock worth $1,384,000 after acquiring an additional 8,000 shares during the period. Cubist Systematic Strategies LLC lifted its stake in shares of Janux Therapeutics by 88.0% in the 1st quarter. Cubist Systematic Strategies LLC now owns 75,860 shares of the company’s stock valued at $2,048,000 after purchasing an additional 35,511 shares during the period. Geode Capital Management LLC boosted its position in shares of Janux Therapeutics by 15.5% during the 2nd quarter. Geode Capital Management LLC now owns 902,312 shares of the company’s stock valued at $20,845,000 after purchasing an additional 121,403 shares in the last quarter. AlphaQuest LLC grew its stake in Janux Therapeutics by 3,658.9% during the second quarter. AlphaQuest LLC now owns 9,698 shares of the company’s stock worth $224,000 after purchasing an additional 9,440 shares during the period. Finally, Deutsche Bank AG increased its holdings in Janux Therapeutics by 7.2% in the first quarter. Deutsche Bank AG now owns 99,691 shares of the company’s stock worth $2,692,000 after purchasing an additional 6,662 shares in the last quarter. 75.39% of the stock is owned by institutional investors.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.